このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Immunotherapy With Glatiramer Acetate in PLWHIV in Poor Immunological Responders on Antiretroviral Therapy (GEODE)

2026年9月25日 更新者:ANRS, Emerging Infectious Diseases

Immunotherapy With Glatiramer Acetate in PLWHIV in Poor Immunological Responders on Antiretroviral Therapy: a Phase II, Multicenter, Randomized, Open-label, Pilot Clinical Trial

The purpose of this trial is to evaluate the immunomodulatory effects of glatiramer acetate (GA) in improving the recovery of CD4 T cells and the CD4/CD8 ratio in people living with HIV (PLWHIV) who have poor immune recovery and persistent immune activation, despite virologically effective antiretroviral (ARV) treatment.

ANRS 0766s GEODE is a Pilot, multicenter, randomised and open-label clinical trial:

Participants will be randomized 2:1 to either one of the two parallel arms

  • Arm A (24 participants) : Glatiramer Acetate (GA)
  • Arms B (12 participants) : control

Randomisation of the trial arms:

The participants will be randomised in an open-label trial in a 2:1 ratio with, for each arm, a distribution by age group (< 50 and = or > 50 years) using a minimisation randomisation method.

The trial will consist of three phases:

Phase I: A first controlled phase in which participants in arm A will receive subcutaneous injections of GA three times a week for 16 weeks, and will be compared with participants randomised to arm B who do not receive GA (control group). The primary endpoint will be assessed at week 16 (end of the controlled phase).

Phase II: A second post-interventional observational phase will begin after W16 to evaluate a potential post-treatment effect and its duration in arm A.

During this phase, the efficacy of the strategy during the phase I will be analysed for all participants (once the last randomised participant has reached week 16).

It will continue until the potential opening of the phase III extension, in the event of efficacy be confirmed, or until the decision to terminate the trial if this is not the case.

Phase III: An optional third extension phase may be offered to participants in both arms. The opening of this phase will be conditional upon prior demonstration of a global benefit between both treatment groups during Phase I. During this optional phase III, participants in arm A will be offered a second cycle of GA and those in arm B, a first cycle of GA at the same frequency as a subcutaneous injection three times a week for 16 weeks. Participation in this phase will be optional.

All participants will continue their current antiretroviral treatment.

調査の概要

状態

まだ募集していません

条件

介入・治療

研究の種類

介入

入学 (推定)

36

段階

  • フェーズ2

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Âge > or = to 18 years,
  • HIV-1 infection,
  • Receiving ART,
  • Have a sustained HIV-1 plasma viral load <50 copies/mL on ART for more than 3 years (blips <400 copies/mL allowed),
  • Have a blood CD4 T cell count <500 cells/μL (at the last three time points analyzed, including the screening visit, in the 18 months),
  • Have a blood CD4/CD8 T cell ratio <0.5 (at the last three time points analyzed, including the screening visit, in the past 18 months),
  • Willing to receive treatment via subcutaneous injections three times a week, to adhere to the study schedule, and to accept blood samples in accordance with the protocol,
  • Informed and written consent signed by the participant and the investigator (no later than the day of the enrolment visit and prior to any examination to be carried out as part of the trial) (Article L1122-1-1 of the Public Health Code),
  • Participant covered by health insurance (Article L1121-11 of the Public Health Code).

Exclusion Criteria:

  • HIV-2 infection,
  • Age >65 years (to avoid lack of immune reconstitution due to immunosenescence),
  • Hypersensitivity to glatiramer acetate or to its excipient: mannitol,
  • Current treatment with systemic corticosteroids, or during the 12 weeks prior to randomisation,
  • Current treatment with immunosuppressants, or during the 12 weeks prior to randomisation,
  • History of chemotherapy or radiation therapy (any date),
  • History of hematologic disorders (e.g. lymphoma, leukemia, Bone marrow transplant, solid organ transplant),
  • History of cancer (except cancer that was cured by surgery alone more than 5 years ago; cutaneous epidermoid carcinoma; carcinoma in situ; Kaposi sarcoma that resolved without chemotherapy or radiation therapy),
  • Chronic hepatitis B (positive HBs antigen) or hepatitis C (positive HCV RNA); cirrhosis (including non-viral causes),
  • Active opportunistic infections with risk of severe immune reconstitution inflammatory syndrome (tuberculous neuromeningitis or cryptococcal neuromeningitis),
  • Pregnancy or intention to be pregnant during the study period
  • Participation in any other clinical trial of an investigational agent or in any interventional or non-interventional study requiring additional blood sampling. Participation in an observational study without additional blood sampling is permitted.
  • Participants under guardianship or curatorship or under judicial protection,
  • Renal failure : eGFR < 30 mL/min/1.73 m² (CKD-EPI formula)

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Arm A (24 participants) : GLATIRAMER VIATRIS 40mg/ml

Participants will receive GA via subcutaneous injections (40 mg/ml), three times a week, for 16 weeks in addition to their current antiretroviral treatment.

Participants will receive GA via subcutaneous injections (40 mg/ml), three times a week, for 16 weeks in addition to their current antiretroviral treatment. The first injection will be administered in hospital under medical supervision. Subsequent injections will be self-administered by participants at home. An injection pen to facilitate subcutaneous injections will be provided to participants.

介入なし:Arms B (12 participants) : control

Control group (Arm B): The participants will continue their current antiretroviral treatment.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in the CD4/CD8 ratio between W0 and W16 (intra-patient difference between the CD4/CD8 ratio at Week16 and Week0).
時間枠:16Weeks

Change in the CD4/CD8 ratio between Week0 and Week16 (intra-patient difference between the CD4/CD8 ratio at Week16 and Week0).

16Weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年12月1日

一次修了 (推定)

2028年12月15日

研究の完了 (推定)

2030年12月15日

試験登録日

最初に提出

2026年9月1日

QC基準を満たした最初の提出物

2026年9月25日

最初の投稿 (実際)

2026年10月1日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月1日

QC基準を満たした最後の更新が送信されました

2026年9月25日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • ANRS 0766s GEODE

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。